We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Axcella Health Inc | NASDAQ:AXLA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.58 | 4.50 | 4.51 | 0 | 01:00:00 |
From May 2022 to May 2024
By Denny Jacob
Axcella Health Inc. shares surged 53% to 66 cents in after-hours trading Monday after the company said it received regulatory guidance from the U.K.'s regulatory agency for AXA1125 as a treatment for long Covid fatigue.
The clinical-stage biotechnology company said the Medicines and Healthcare products Regulatory Agency issued guidance supporting a single trial that could serve as the registration trial for patients with long Covid fatigue. It said it will meet with the agency in the near term to discuss the innovative licensing and access pathway application.
Axcella also said it reported submission of an investigational new drug application to the U.S. Food and Drug Administration for a Phase 2b/3 trial.
Shares, which closed up 2.4% to 43 cents, are down 73% over the last 12 months.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 23, 2023 16:48 ET (21:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Axcella Health Chart |
1 Month Axcella Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
